StreetAlpha.app
Home › Stocks › AUTL

Autolus Therapeutics plc (AUTL)

Healthcare
$1.09
▼ −5.63%
LAST CLOSE · NOV 17

Autolus Therapeutics develops and makes T cell therapies for cancer and autoimmune diseases, and sells AUCATZYL for leukemia. It last closed at $1.09 on Nov 17, down 5.63% on the day.

AI Auto Pilots
Is AUTL in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$137.4M
+168.8% vs a year ago
Net income
−$256.1M
−186.4% margin
EPS (diluted)
−$0.96
Free cash flow
−$180.2M
−131.1% margin
Valuation
Market cap
$290.3M
266.3M shares
P/E
–
No P/E while losing money
Price to sales
2.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$245.4M
At Sep 30
Shareholder equity
$27.4M
Shares outstanding
266.3M
At Nov 9
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $1.7M$1.7MFY2023FY2024: $10.1M$10.1MFY2024FY2025: $75.4M$75.4MFY2025

From AUTL's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Last report
Nov 10
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
—
No ratings in 90 days
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
No firm has rated AUTL in the past 90 days.
Average 12-month target
No price targets on AUTL in the past 90 days.
Latest rating changes
HC Wainwright & Co.Reiterated
Aug 3Buy$10
DateFirmActionRatingPrice target
Aug 3HC Wainwright & Co.ReiteratedBuy$10
Loading…

Technical Analysis

AUTL · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 27% below its 20 day and 52% below its 50 day average. It is 52% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 22), oversold. The nearest support is the 52 week low at $1.07, and the nearest resistance the Pivot at $1.11.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 9.5%/day
Key levels
$2.5852 week high+136.7%
$1.77100 day average+62.4%
$1.6650 day average+52.3%
$1.66200 day average+52.3%
$1.3920 day average+27.5%
$1.38Swing high (Nov 10)+26.6%
$1.13Pivot R1+3.7%
$1.11Pivot+1.8%
$1.09Last close
$1.0752 week low−1.8%
$1.06Pivot S1−2.8%
Indicators
RSI (14)22.17Oversold below 30Oversold
MACD-0.15Below its signal lineBearish
Stochastic9.2Near the bottom of its rangeOversold
ADX (14)45.1Strong downtrend
Williams %R-96.5Oversold below −80, overbought above −20Oversold
CCI (20)-125.4Oversold below −100, overbought above 100Oversold
Rate of change−23.0%Change over 10 sessionsBearish
ATR (14)$0.10Typical daily range, 9.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for AUTL

What happened before

See how AUTL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow AUTL usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How AUTL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in AUTL in the last 90 days.

Loading…

See today’s whale options flow across the market →

AUTL Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲44 buying vs 33 selling
  • ●Held by funds -0.3 pts
  • ▲Funds holding +7
  • ▲Superinvestors: 4 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding9184+8.3%
In funds' top 10330.0%
Held by funds49.3%49.6%−0.3 pts
New / increased16 / 289 / 27+22.2%
Reduced / sold out23 / 1021 / 10+6.5%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See AUTL institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AUTL is in one of them and how their past AUTL trades turned out.

AUTL in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered AUTL in an article yet. Here's the latest on the wider market.

About Autolus Therapeutics

Autolus Therapeutics is a biopharmaceutical company based in London, United Kingdom. It develops and manufactures cell therapies that reprogram a patient's own T cells so they can recognize and attack target cells. Its main product, AUCATZYL, is approved to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia in the United States and the United Kingdom. The company is also testing its therapy in other cancers and in autoimmune diseases such as lupus and multiple sclerosis.

Headquarters
London, United Kingdom